Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HELOISE: Trastuzumab dosing in metastatic gastric cancer
NCT01450696Phase 3Terminated
- Sponsor
- Roche
- Start
- Dec 2011
- Primary completion
- Feb 2015
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 25
01
Overview
A Phase 3 trial of trastuzumab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Roche. Started Dec 2011; status: terminated.
02
Drugs
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT01450696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01450696.